Drug Profile


Alternative Names: AM-94; RV3-BB

Latest Information Update: 04 Oct 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Murdoch Childrens Research Institute
  • Developer Murdoch Childrens Research Institute; Zenyth Therapeutics
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Rotavirus infections

Most Recent Events

  • 06 Jul 1999 SmithKline Beecham has decided not to exercise its option to license AM94 from Amrad, which has prompted the latter company to discontinue development of the vaccine
  • 06 Jul 1999 Discontinued-II for Rotavirus infections in Australia (PO)
  • 03 Oct 1997 Phase-II clinical trials for Rotavirus infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top